Clinical Trials Logo

Anxiety Disorders clinical trials

View clinical trials related to Anxiety Disorders.

Filter by:

NCT ID: NCT01875796 Completed - Anxiety Disorders Clinical Trials

Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders

Start date: June 2013
Phase: Phase 1
Study type: Interventional

This project tests the feasibility and utility of a novel, integrated approach to treatment of patients with cannabis use disorder (CUD) and anxiety disorders.

NCT ID: NCT01866605 Completed - Anxiety Clinical Trials

A Study of Methods to Reduce Anxiety in Preoperative Elective Surgical Patients

Start date: July 2008
Phase: Phase 4
Study type: Interventional

Patients are often anxious immediately before surgery. The investigators hypothesis is that a warming blanket is as effective as the sedative midazolam in allaying anxiety before surgery.

NCT ID: NCT01863459 Completed - Clinical trials for Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders

Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity

Start date: April 2013
Phase: Phase 4
Study type: Interventional

1. To evaluate the safety, and efficacy of Lisdexamfetamine dimesylate in the treatment of outpatients with DSM-IV ADHD with anxiety and depressive disorder comorbidity, as well as to evaluate the effects on quality of life . 2. To evaluate the efficacy of Lisdexamfetamine dimesylate in the treatment of anxiety and depressive disorders which commonly occur with ADHD. 3. To examine the potential relationship between telomere length and Adult ADHD with comorbidity and the potential effect of treatment response. 4. To examine the potential associations with specific genes and Adult ADHD.

NCT ID: NCT01858857 Recruiting - Depression Clinical Trials

Geriatric Psychiatry and Pharmacovigilance

GAP
Start date: May 2013
Phase: N/A
Study type: Observational

The purpose of this observational multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment. The aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises. To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites. At Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed. Afterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system. In case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually. 2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data.

NCT ID: NCT01856530 Completed - Clinical trials for Social Anxiety Disorder

Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder

Start date: July 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to learn more about how the hormone, oxytocin, impacts social behavior in terms of cooperation with others, attention processing, and reward processing, among patients with social anxiety disorder. Based on available research, the investigators predict that in patients with social anxiety disorder, oxytocin will improve social cooperation during an online ball-tossing game called Cyberball, reduce attention toward socially threatening cues during a dot-probe task, and lead to greater willingness to work for monetary rewards for others rather than themselves during an effort expenditure task.

NCT ID: NCT01853956 Completed - Anxiety Disorders Clinical Trials

Bioequivalence Trial of Alprazolam 0.25 mg Tablets

Start date: December 2, 2010
Phase: Phase 1
Study type: Interventional

The objective of this study was to confirm if two formulations of alprazolam (tablets) are bioequivalent. Test product was Zamoprax® 0.25 mg (GlaxoSmithKline) and reference product Tafil® 0.25 mg (Pharmacia & Upjohn). One tablet was the single dosage. The study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fasting conditions. The population was composed of 28 healthy volunteers, both genders, adults between 18-50 years. The comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.

NCT ID: NCT01850355 Active, not recruiting - Anxiety Clinical Trials

An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

Start date: July 2013
Phase: N/A
Study type: Interventional

The main objective of this exploratory 8-week pilot study is to evaluate the safety and efficacy of buspirone for the treatment of anxiety in youth (ages 6-17 years) with autism spectrum disorders. The study results will be used to generate hypothesis for a larger randomized controlled clinical trials with explicit hypotheses and sufficient statistical power.

NCT ID: NCT01849432 Completed - Clinical trials for Posttraumatic Stress Disorder

Study of Brain Circuitry in Anxiety Disorders

Start date: December 2006
Phase: N/A
Study type: Observational

A diverse body of research has implicated the amygdalo-cortical circuitry in the pathophysiology of anxiety disorders. For example, one model of PTSD posits exaggerated amygdala responsivity to threat-related stimuli as well as deficient top-down modulation of amygdala responses by specific cortical regions, including the pregenual anterior cingulate cortex, subcallosal cortex, and hippocampus. The investigators propose to investigate the pathophysiology of several specific anxiety disorders, Posttraumatic Stress Disorder (PTSD), Panic Disorder (PD), and Specific Phobia(SP), by using cognitive activation paradigms and magnetic resonance imaging (MRI) to probe the function and structure of implicated amygdalo-cortical circuitry.

NCT ID: NCT01844115 Completed - Clinical trials for Generalized Anxiety Disorder

Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Start date: April 30, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).

NCT ID: NCT01837966 Active, not recruiting - Surgery Clinical Trials

Randomized, Placebo-Controlled Study: Effects of Lavender Aromatherapy on Preoperative Anxiety in Breast Patients

Start date: January 2013
Phase: N/A
Study type: Interventional

The study is designed to see if lavender aroma therapy reduces pre-operative anxiety in breast surgery patients.